PHILADELPHIA -- Patients were harmed when given rivaroxaban (Xarelto) to prevent valve surface thromboembolism after transcatheter aortic valve replacement (TAVR) if they had no established indication ...

PHILADELPHIA, PA—Rivaroxaban (Xarelto; Bayer/Janssen) is not the answer to the question of how best to treat patients after a successful TAVR, the full results of the prematurely stopped GALILEO trial ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Among patients who underwent successful transcatheter aortic valve replacement and were not on ...

The phase 3 GALILEO trial has been terminated early after a preliminary analysis showed that rivaroxaban (Xarelto; Bayer/Janssen) was associated with an increase in all-cause death, thromboembolic ...

Xarelto (rivaroxaban) and Eliquis (apixaban) are prescribed to prevent or treat blood clots in adults. Both Xarelto and Eliquis also have approved uses for children. Both drugs are also used to lower ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...

Xarelto (rivaroxaban) may increase the risk of bleeding, especially when combined with alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet drugs, other blood thinners, and ...